Human Preadipocytes from donors with Type 2 Diabetes (HPAd-T2D) are donor-derived human adipose precursor cells that provide a relevant in vitro system for studying adipocyte biology in the context of type 2 diabetes, diabetes mellitus, and metabolic disease. HPAd-T2D are derived from human adipose tissue sources such as subcutaneous adipose tissue and visceral adiposity depots, and they support adipocyte differentiation into adipocyte states ranging from preadipocytes to differentiated adipocytes and mature adipocytes. This enables investigation of how type 2 diabetes status and donor-associated metabolic features affect adipocyte function, lipid droplet biology, lipid accumulation, and lipid metabolism, as well as how these changes contribute to disrupted metabolic homeostasis and impaired insulin response.
A central focus in HPAd-T2D research is insulin resistance and insulin signaling dysregulation. Because adipocytes are key tissues for glucose handling, HPAd-T2D are well suited to examine basal glucose uptake and insulin stimulated glucose uptake, along with insulin receptor–dependent insulin response pathways that govern glucose metabolism. By measuring changes in gene expression and functional readouts across adipocyte differentiation, researchers can evaluate how diabetes and insulin resistance shape insulin sensitivity and insulin response, including peripheral insulin-responsive signaling that supports glucose metabolism and insulin action rather than insulin secretion. These studies help clarify how insulin resistance in human adipose tissue relates to glucose tolerance, glucose metabolism, and broader diabetes-associated metabolic outcomes relevant to obese individuals and other diabetes risk factor populations.
HPAd-T2D can also be used to probe how immune cells and inflammatory cues intersect with adipocyte biology in diabetes. In this donor context, inflammation associated with diabetes and metabolic disease can influence adipocyte differentiation programs, adipocyte lipolysis, and the balance of lipid droplet formation and breakdown, thereby shaping adipocyte function and insulin sensitivity. By capturing donor-derived diabetes status and metabolic features, HPAd-T2D support mechanistic investigation of altered adipocyte biology, impaired insulin signaling, and changes in adipocyte lipolysis and lipid metabolism that contribute to disrupted metabolic homeostasis and diabetes-associated systemic glucose dysregulation.
Human Preadipocytes (HPAd) provide ideal cell models and facilitate life science research and drug discovery for obesity, diabetes and cardiovascular diseases. We derive HPAd from human subcutaneous and heart adipose tissue and cryopreserve these fibroblast-like precursor cells at the end of primary culture. They can propagate two passages prior to differentiating into Human Adipocytes (HAd). Complete differentiation can be easily achieved through the use of Preadipocyte Differentiation Medium. Mature HAd are expected 10 days after induction of differentiation and should remain healthy and responsive for at least 2 weeks after complete differentiation. Adipose mass can be controlled by inhibition of HPAd differentiation and increase of lypolysis. HPAd are also available prescreened for expression of adipocyte markers.
HPAd-s-T2D
HPAd from Cell Applications, Inc. have been used in multiple studies investigating the cellular basis of diabetes and obesity, as well as mechanisms of action of various drug candidates. For example, it was shown that:
Interaction between infiltrating monocytes and adipocytes affects production of metalloproteinases and osteopontin, a proinflammatory cytokine, which ultimately leads to development of more adipose tissue and insulin resistance
Adipocyte differentiation requires activation of Akt1 through the mTORC2-BSTA mechanism, leading to downstream suppression of FoxC2
Instead of protecting from hyperglycemia-induced ER stress, like it does in other cells, in adipocytes a bioactive, endogenously produced compound taurine was shown to modulate the expression of adipokines under inflammatory conditions by inhibiting the STAT-3 signaling pathway (Kim, 2013a,c), and to inhibit differentiation of preadipocytes into adipocytes
FGF21, which leads to reduction of body weight in animal models of obesity, was shown to act by modulating gene expression, phosphorylating Frs2a, Erk1/2, and Mypt1 and by increasing oxidative capacity of adipocytes via AMPK–SIRT1–PGC1a cascade
Atrial natriuretic peptide (ANP) regulates lipid catabolism and reduce insulin resistance in HPAd by activating AMPK
Adipocytokines are involved in normal pregnancy and pregnancy-induced hypertension
Lotus seed extract exhibits anti-obesity and hypolipidaemic properties
HPAd (along with our Human Dermal Fibroblasts) demonstrate the role of epigenetic modifications in increasing efficiency of iPS reprogramming
Type 2 Diabetes (T2D) Cellular Disease Models For T2D research and drug discovery, Cell Applications offers multiple cell types, isolated from donors where genetics and lifestyle factors contributed to insulin resistance and high blood sugar levels.
Details
Tissue
Human adipose tissue from donor with Type 2 Diabetes (T2D)
QC
No bacteria, yeast, fungi, mycoplasma, virus
Character
Positive for lipid drops in cytoplasm & Oil Red O Staining, in Differentiation Med
Bioassay
Attach, spread, proliferate in Growth Med
Cryovial
500,000 HPAd (2nd passage) frozen in Basal Medium w/ 20% FBS, 5% DMSO
Kit
Cryovial frozen HPAd-T2D (802hT2D-05a or 802sT2D-05a), Growth Medium (811-500), Subcultr Rgnt Kit (090K)
Proliferating
Shipped in Gr Med, 3rd psg (flasks or plates)
Doublings
Can be cultured 2 passages before differentiation into HAd
Applications
Laboratory research use only (RUO). Not for human, clinical, diagnostic or veterinary use.